Primary sarcomas of the sellar region are uncommon, although a wide variety have been reported. To date, no cases of primary synovial sarcoma have been described as occurring at this site. We report an immunohistochemically and molecular genetically confirmed primary synovial sarcoma involving the sellar/parasellar region and cavernous sinus in an adult male. Subtotal resection and radiosurgery proved to be efficacious. The spectrum of primary sellar region sarcomas is summarized. Neuro-Oncology 9, 454-459, 2007 (Posted to NeuroOncology [serial online], Doc. D06-00171, August 17, 2007. URL http://neuro-oncology.dukejournals.org; DOI: 10.1215 DOI: 10. /15228517-2007 Keywords: immunohistochemistry, sarcoma, sella, synovial sarcoma, treatment S kull base involvement by malignant tumors is usually the result of direct extension or metastatic disease. Well-recognized primary sarcomas involving this site, particularly the sella, include chordoma, chondrosarcoma, osteosarcoma, and a variety of postirradiation tumors, mainly fibrosarcomas. Pertinent to this report is but a single case of soft tissue synovial sarcoma metastatic to the sella. 1 In this case report, we describe the first example of primary synovial sarcoma involving the sella/parasellar region, as well as the cavernous sinus. The morphologic diagnosis of synovial sarcoma was con- firmed by immunohistochemistry and molecular genetics, which showed the diagnostic X;18 translocation. The patient, an adult male, initially responded favorably to subtotal resection and radiosurgery but has experienced a recurrence.
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Case Study
A 48-year-old Caucasian male presented to the neurosurgical clinic with a 3-month history of right-sided headache and blurred vision. Neurologic and visual field examinations revealed mild right sixth nerve palsy, ptosis, and left hemianopsia. General laboratory values were normal, as was anterior and posterior pituitary function. A CT scan revealed a 3.5-cm irregular, contrastenhancing mass involving the sella and right parasellar region. Punctate tumoral calcification was noted (Fig.  1) . Further, MRI evaluation better defined the mass and showed involvement of the right cavernous sinus. Right optic nerve and chiasmal compression was also noted, as was narrowing (up to 60%) of the cavernous carotid artery throughout its course ( Fig. 2A-C) . Nonetheless, an MR angiogram showed normal blood flow. A right pterional craniotomy with subtotal (90%) resection of the mass was performed to decompress the optic nerve and obtain a diagnosis. The procedure was performed without complication.
A diagnosis of synovial sarcoma was made (see below). Because synovial sarcomas are often metastatic, an extensive radiographic workup was conducted; no other lesions were identified. Given the aggressive nature of the tumor, a more radical excision was undertaken after balloon test occlusion of the right carotid artery. Although no cross-filling occurred, monitoring over the 20-minute period of occlusion revealed no neurologic effect. A right orbitozygomatic osteotomy and Dolenc procedure were performed. [2] [3] [4] Proximal control of the carotid artery was achieved through exposure of the petrous apex. The third, fourth, and fifth cranial nerves were grossly invaded by tumor and could not be salvaged. The adventitia of the cavernous carotid artery was also grossly infiltrated but was not resected because it had remained patent. Postoperative MRI scans showed only focal residual tumor on the carotid artery. Adjunctive, single-dose, image-guided radiosurgery (1,800 cGy to the 50% isodose line; maximum dose, 3,600 cGy) to the residual tumor and its bed (treatment volume, 6.3 cm 3 ) was undertaken. With the exception of right ophthalmoplegia, the patient remained neurologically intact for 11 months, with no evidence of regrowth on MRI scan. Thereafter, a recurrence was noted just outside the original radiation field involving the skull base, and an exophytic retroclival extension caused compression upon the anterior pons. He continued to remain neurologically stable. Two weeks later, he underwent a subtotal tumor resection via a retrosigmoid approach to decompress the brainstem. The patient has since experienced progressive dysphagia. 
Discussion
Synovial sarcoma is an uncommon soft tissue tumor, accounting for 5%-10% of malignant examples. Young adults are primarily affected, with a mean age of 30 years. Seventy-five percent occur near large joints, mainly of the lower extremities. Most of the remainder involve the trunk and the head and neck region with equal frequency, 4 primarily the paravertebral and the retro-and parapharyngeal regions. Sinuses may also be affected. 6 For the purpose of treatment planning, imaging of sarcomas of the cranial base requires both CT scan and MRI scanning. In the case of synovial sarcoma, a CT scan will identify calcifications in approximately onethird of cases. 7 Only a minority are bone destructive. In soft tissue lesions, MRI shows variation in intensity and enhancement, as well as frequent septation. 8 Most tumors are relatively iso-or hypointense compared to muscle and iso-or slightly hyperintense compared to fat and, in cystic areas, show a high fluid signal. 9 If resection of the carotid artery is considered, angiography with balloon test occlusion should also be performed, which typically shows prominent vascularity.
Confirming the diagnosis of synovial sarcoma relies upon histologic and immunochemical features, 10, 11 and in some cases, molecular genetic analysis, as well. 5 Three histologic patterns are recognized: the classic biphasic form with distinct epithelial and spindle cell components, and monophasic tumors of fibrous or epithelial type. The former occur with equal frequency, whereas the latter is rare. Our tumor is a biphasic example.
The growth rate of synovial sarcomas is often slow, belies their degree of malignancy, and precludes a timely diagnosis. The tumors are variably aggressive. Five-year survival rates cited often range from 40% to
Materials and Methods
The formalin-fixed, routinely processed specimen was cut at 5 μm and stained with hematoxylin and eosin (H&E), Gomori reticulin, and periodic acid-Schiff with and without diastase digestion. Immunohistochemistry (streptavidin-biotin peroxidase complex method) utilized antisera directed against epithelial membrane antigen (EMA; Dako, Carpinteria, CA; 1:20, E29) keratin (AE1-AE3; Zymed, South San Francisco, CA; 1:200), vimentin (Dako; 1:500, 3B4), chromogranin (Roche, Indianapolis, IN; 1:1000, LK2H10), S-100 protein (Dako; 1:800, polyclonal), glial fibrillary acidic protein (Dako; 1:800, polyclonal), p53 protein (Dako; 1:200, DO-7), and Ki-67 (MIB-1; Dako; 1:800).
RNA extraction and reverse transcriptase (RT)-PCR seeking synovial sarcoma fusion transcripts SYT-SSX1 and SYT-SSX2 were performed as previously described.
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Results
The first specimen consisted of fragments, the largest measuring 1.3 3 0.9 3 0.7 cm, and the second, 1 cm 3 in aggregate. H&E-stained sections showed a biphasic, spindle-and epithelial-appearing tumor. The former consisted of cytologically uniform cells disposed in sheets and pseudopapillary arrangements in which an often single layer of neoplastic cells overlay a mucoid to fibrous, perivascular stoma (Fig. 3A) . In other areas, sheets of tumor cells lay enmeshed in collagen (Fig. 3B) . True glands were not seen. The spindle cell element was monomorphous. Few mitoses were noted (1/10 highpower fields at 3 3 40) . No necrosis was encountered. Immunostains showed cytoplasmic staining for keratin (Fig. 4A ) and membrane reactivity for EMA (Fig. 4B) . All other markers but MIB-1 (labeling index, 22%) were immunonegative. 
Molecular genetics studies (RT-PCR analysis) dem-
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. [12] [13] [14] [15] Local recurrence is frequent, and metastasis is common. 14, 16 Primary treatment of soft tissue examples involves aggressive resection with free margins. [17] [18] [19] Unfortunately, skull base tumors may not be resectable. This is especially true of tumors of any kind involving the cavernous sinus region. Since synovial sarcoma rarely affects the sella, little is known regarding optimal treatment. One example secondarily affecting the parasellar area and orbit has been reported. 1 It was a metastasis of a primary soft tissue monophasic synovial sarcoma of soft tissue operated on 16 months before. Treatment consisted of decompression of the cavernous sinus and radiation therapy. At 6-month follow-up, an MRI scan with contrast showed no tumor recurrence. In our case, an orbitozygomatic osteotomy combined with a Dolenc procedure allowed extensive bone removal and access to the cavernous sinus. Unfortunately, balloon test occlusion showed no cross-filling. Every attempt to preserve a tumor-free carotid artery was made, but due to adherence of residual tumor to its adventitia, a complete resection was not possible.
Adjunctive treatments may be required. Radiation and chemotherapy have been studied and do result in local control. 16, [19] [20] [21] However, improved survival has not been seen. 16, 20, 22 Advances in radiosurgery, specifically, imageguided robotic radiosurgery, allow for more accurate, aggressive treatment in the cranial base. No data are available to confirm whether this will be beneficial.
The lion's share of sellar tumors are pituitary adenomas. Their characteristic endocrine and radiographic abnormalities, coupled with lack of diabetes insipidus, distinguishes them for a wide variety of tumors affecting this anatomically complex region. Mesenchymal tumors occurring at this site include primarily meningiomas 23 and hemangiopericytomas. [24] [25] [26] [27] The former are far more often benign or atypical than malignant, 28 whereas the latter are malignant by definition, occurring in low-and high-grade forms. 24, 25, 29 A variety of other benign and malignant mesenchymal tumors, arising either in dura or in bone, occasionally affect the sellar region. 30 45 A similar variety of sellar region sarcoma arises after radiotherapy, nearly always for pituitary adenoma. The relative and cumulative risk of their development has been calculated. 46 The minimal therapeutic dose is approximately 3,000 cGy. 47 The latency period from adenoma irradiation to presentation of the sarcoma varies greatly, ranging from as little as 2 years to as many as 40 years. 48 Most examples are fibrosarcomas intimately associated with residual adenoma, 47, 49 but osteosarcoma 48,50-52 and even leiomyosarcoma 25 have also been reported. Fatal tumors often vary in their rate of progression and frequently recur but tend not to metastasize.
Conclusion
The spectrum of skull base sarcomas, particularly of the sellar region, is highly varied. Synovial sarcoma of the skull base is a rarely encountered entity. Most result in metastatic disease. This is the first reported case of synovial sarcoma involving the sella and parasellar region, as well as the cavernous sinus. The diagnosis was confirmed by both immunohistochemistry and molecular genetic testing. In that a complete resection could not be accomplished, it was felt that image-guided robotic radiosurgery would be appropriate, although its use has not previously been reported.
